文献速递妇科

原发HPV筛查与细胞学筛查效果相似——随机宫颈癌筛查试验的长期随访

Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
PubMed 文献 · Gynecol Oncol · 2023-12-12

芬兰随机HPV筛查试验对2003—2008年南芬兰逾236,000名个体1:1随机分组,比较HPV与细胞学筛查。死亡率比1.01,95%CI 0.61-1.64)。在细胞学筛查体系成熟、宫颈癌低发地区,两种筛查效果相似,HPV筛查具客观性和自采样优势,但需关注获益与危害的平衡。

要点

  • 在细胞学筛查成熟、宫颈癌低发地区,HPV筛查与细胞学筛查效果相似。
  • HPV组与细胞学组宫颈癌发病率比1.08(95%CI 0.85-1.37),死亡率比1.01(95%CI 0.61-1.64)。
  • HPV筛查提供客观、经过验证的检测系统并支持自采样,可提高筛查覆盖率。

核心结论

  • 在细胞学筛查体系成熟、宫颈癌低发地区,HPV筛查与细胞学筛查显示相似效果。
  • HPV筛查提供客观、经过验证的检测系统并支持自采样,可提高筛查覆盖率,但仍需关注获益与危害的平衡。

研究设计与样本

  • 芬兰随机HPV筛查试验的长期随访,为常规筛查规划内开展的首个HPV筛查试验。
  • 2003—2008年间在南芬兰将逾236,000名个体按1:1随机分配至HPV筛查组和细胞学筛查组。
  • 采用泊松回归计算宫颈癌发病率和死亡率比。

主要发现

  • 与细胞学组相比,HPV组宫颈癌发病率比1.08(95%CI 0.85-1.37)。
  • 与细胞学组相比,HPV组宫颈癌死亡率比1.01(95%CI 0.61-1.64)。

临床怎么用

  • 原文未据此给出推荐,仅指出在细胞学筛查成熟、宫颈癌低发地区两种筛查效果相似,HPV筛查可提高筛查覆盖率,并需关注获益与危害的平衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term effects of primary human papillomavirus (HPV) screening on cervical cancer incidence and mortality are still missing. We conducted a long-term follow-up of the Finnish randomized HPV screening trial, the first HPV screening trial run within the routine screening program, to assess these measures. METHODS: During 2003-2008, over 236,000 individuals were randomized (1:1) to HPV and cytology screening arms in Southern Finland. To compare the study arms, we calculated the cervical cancer incidence and mortality rate ratios using Poisson regression. RESULTS: During a total of 3.5 million person-years of follow-up, we observed 129 cervical cancers and 32 cervical cancer deaths in the cytology arm, 139 cervical cancers and 32 cervical cancer deaths in the HPV arm. Compared to the cytology arm, in the HPV arm, the incidence rate ratio was 1.08 (95% CI 0.85-1.37), and the mortality rate ratio was 1.01 (95% CI 0.61-1.64). CONCLUSIONS: We studied the effects of HPV screening on both cervical cancer incidence and mortality for the first time in a setting with an already well-established, high-quality cytology screening program. In this kind of setting with a low incidence of cervical cancer, HPV and cytology screening showed similar effectiveness. HPV screening provides, however, an objective, validated test system and enables self-sampling which can improve screening coverage. More attention is needed yet to ensure the balance between the harms and benefits of HPV screening.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Vahteristo M, Leinonen MK, Sarkeala T, et al. Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial. Gynecol Oncol. 2023. PMID: 38091774. doi:10.1016/j.ygyno.2023.11.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。